Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries

We are analyzing https://link.springer.com/article/10.1007/s00213-007-0729-8.

Title:
Prenatal exposure to an NMDA receptor antagonist, MK-801 reduces density of parvalbumin-immunoreactive GABAergic neurons in the medial prefrontal cortex and enhances phencyclidine-induced hyperlocomotion but not behavioral sensitization to methamphetamine in postpubertal rats | Psychopharmacology
Description:
Rationale Neurodevelopmental deficits of parvalbumin-immunoreactive γ-aminobutyric acid (GABA)ergic interneurons in prefrontal cortex have been reported in schizophrenia. Glutamate influences the proliferation of this type of interneuron by an N-methyl-d-aspartate (NMDA)-receptor-mediated mechanism. The present study hypothesized that prenatal blockade of NMDA receptors would disrupt GABAergic neurodevelopment, resulting in differences in effects on behavioral responses to a noncompetitive NMDA antagonist, phencyclidine (PCP), and a dopamine releaser, methamphetamine (METH). Methods GABAergic neurons were immunohistochemically stained with parvalbumin antibody. Psychostimulant-induced hyperlocomotion was measured using an infrared sensor. Results Prenatal exposure (E15–E18) to the NMDA receptor antagonist MK-801 reduced the density of parvalbumin-immunoreactive neurons in rat medial prefrontal cortex on postnatal day 63 (P63) and enhanced PCP-induced hyperlocomotion but not the acute effects of METH on P63 or the development of behavioral sensitization. Prenatal exposure to MK-801 reduced the number of parvalbumin-immunoreactive neurons even on postnatal day 35 (P35) and did not enhance PCP-induced hyperlocomotion, the acute effects of METH on P35, or the development of behavioral sensitization to METH. Conclusions These findings suggest that prenatal blockade of NMDA receptors disrupts GABAergic neurodevelopment in medial prefrontal cortex, and that this disruption of GABAergic development may be related to the enhancement of the locomotion-inducing effect of PCP in postpubertal but not juvenile offspring. GABAergic deficit is unrelated to the effects of METH. This GABAergic neurodevelopmental disruption and the enhanced PCP-induced hyperlocomotion in adult offspring prenatally exposed to MK-801 may prove useful as a new model of the neurodevelopmental process of pathogenesis of treatment-resistant schizophrenia via an NMDA-receptor-mediated hypoglutamatergic mechanism.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Education
  • Games
  • Movies

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

The income method remains a mystery to us.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

google, scholar, article, pubmed, cas, schizophrenia, cortex, receptor, nmda, gabaergic, psychiatry, prefrontal, psychopharmacology, neurons, rat, prenatal, behavioral, effects, res, brain, phencyclidineinduced, hyperlocomotion, antagonist, parvalbuminimmunoreactive, receptors, parvalbumin, biol, exposure, sensitization, rats, phencyclidine, meth, development, neurosci, privacy, cookies, content, research, medial, abekawa, interneurons, glutamate, study, blockade, pcp, dopamine, acute, adult, access, cortical,

Topics {✒️}

n-methyl-d-aspartate receptors n-methyl-d-aspartate parvalbumin-immunoreactive γ-aminobutyric acid nmda-receptor-mediated hypoglutamatergic mechanism month download article/chapter ethanol-induced apoptosis neurodegeneration shin nakagawa & tsukasa koyama γ-aminobutyric acid neurotransmission audiogenic seizure-prone balb/ placebo-controlled pilot study enhanced pcp-induced hyperlocomotion enhance pcp-induced hyperlocomotion mammalian alpha-lineage parvalbumin enhances phencyclidine-induced hyperlocomotion parvalbumin-immunoreactive gabaergic neurons gabaa receptor binding phencyclidine-induced dopamine release nmda receptor antagonist nmda receptor antagonists full article pdf noncompetitive nmda antagonist calbindin d-28k article psychopharmacology aims receptor-mediated mechanism mk-801 reduces density privacy choices/manage cookies prenatal exposure phencyclidine-induced hyperactivity gamma oscillations meyer wj iii parvalbumin-immunoreactive neurons ketamine stimulates psychosis psychostimulant-induced hyperlocomotion phencyclidine-induced hyperlocomotion striatal d2 receptor paranoid psychotic state disrupt gabaergic neurodevelopment gabaergic neurodevelopmental disruption nmda receptor blockade article abekawa neuronal migration glutamate receptor dysfunction phencyclidine-induced activation refined crystal structure chronic pcp model clinical research studies α1 adrenaline receptors cortical inhibitory neurons medial prefrontal cortex induced behavioral stimulation

Questions {❓}

  • Farber NB, Wozniak DF, Price MT, Labruyere J, Huss J, St Peter H, Olney JW (1995) Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Prenatal exposure to an NMDA receptor antagonist, MK-801 reduces density of parvalbumin-immunoreactive GABAergic neurons in the medial prefrontal cortex and enhances phencyclidine-induced hyperlocomotion but not behavioral sensitization to methamphetamine in postpubertal rats
         description:Neurodevelopmental deficits of parvalbumin-immunoreactive γ-aminobutyric acid (GABA)ergic interneurons in prefrontal cortex have been reported in schizophrenia. Glutamate influences the proliferation of this type of interneuron by an N-methyl-d-aspartate (NMDA)-receptor-mediated mechanism. The present study hypothesized that prenatal blockade of NMDA receptors would disrupt GABAergic neurodevelopment, resulting in differences in effects on behavioral responses to a noncompetitive NMDA antagonist, phencyclidine (PCP), and a dopamine releaser, methamphetamine (METH). GABAergic neurons were immunohistochemically stained with parvalbumin antibody. Psychostimulant-induced hyperlocomotion was measured using an infrared sensor. Prenatal exposure (E15–E18) to the NMDA receptor antagonist MK-801 reduced the density of parvalbumin-immunoreactive neurons in rat medial prefrontal cortex on postnatal day 63 (P63) and enhanced PCP-induced hyperlocomotion but not the acute effects of METH on P63 or the development of behavioral sensitization. Prenatal exposure to MK-801 reduced the number of parvalbumin-immunoreactive neurons even on postnatal day 35 (P35) and did not enhance PCP-induced hyperlocomotion, the acute effects of METH on P35, or the development of behavioral sensitization to METH. These findings suggest that prenatal blockade of NMDA receptors disrupts GABAergic neurodevelopment in medial prefrontal cortex, and that this disruption of GABAergic development may be related to the enhancement of the locomotion-inducing effect of PCP in postpubertal but not juvenile offspring. GABAergic deficit is unrelated to the effects of METH. This GABAergic neurodevelopmental disruption and the enhanced PCP-induced hyperlocomotion in adult offspring prenatally exposed to MK-801 may prove useful as a new model of the neurodevelopmental process of pathogenesis of treatment-resistant schizophrenia via an NMDA-receptor-mediated hypoglutamatergic mechanism.
         datePublished:2007-03-06T00:00:00Z
         dateModified:2007-03-06T00:00:00Z
         pageStart:303
         pageEnd:316
         sameAs:https://doi.org/10.1007/s00213-007-0729-8
         keywords:
            Prenatal
            MK-801
            NMDA receptor
            Parvalbumin
            PCP
            METH
            Neurosciences
            Pharmacology/Toxicology
            Psychiatry
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00213-007-0729-8/MediaObjects/213_2007_729_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00213-007-0729-8/MediaObjects/213_2007_729_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00213-007-0729-8/MediaObjects/213_2007_729_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00213-007-0729-8/MediaObjects/213_2007_729_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00213-007-0729-8/MediaObjects/213_2007_729_Fig5_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00213-007-0729-8/MediaObjects/213_2007_729_Fig6_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00213-007-0729-8/MediaObjects/213_2007_729_Fig7_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00213-007-0729-8/MediaObjects/213_2007_729_Fig8_HTML.gif
         isPartOf:
            name:Psychopharmacology
            issn:
               1432-2072
               0033-3158
            volumeNumber:192
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Tomohiro Abekawa
               affiliation:
                     name:Hokkaido University
                     address:
                        name:Department of Psychiatry, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Koki Ito
               affiliation:
                     name:Hokkaido University
                     address:
                        name:Department of Psychiatry, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Shin Nakagawa
               affiliation:
                     name:Hokkaido University
                     address:
                        name:Department of Psychiatry, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Tsukasa Koyama
               affiliation:
                     name:Hokkaido University
                     address:
                        name:Department of Psychiatry, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Prenatal exposure to an NMDA receptor antagonist, MK-801 reduces density of parvalbumin-immunoreactive GABAergic neurons in the medial prefrontal cortex and enhances phencyclidine-induced hyperlocomotion but not behavioral sensitization to methamphetamine in postpubertal rats
      description:Neurodevelopmental deficits of parvalbumin-immunoreactive γ-aminobutyric acid (GABA)ergic interneurons in prefrontal cortex have been reported in schizophrenia. Glutamate influences the proliferation of this type of interneuron by an N-methyl-d-aspartate (NMDA)-receptor-mediated mechanism. The present study hypothesized that prenatal blockade of NMDA receptors would disrupt GABAergic neurodevelopment, resulting in differences in effects on behavioral responses to a noncompetitive NMDA antagonist, phencyclidine (PCP), and a dopamine releaser, methamphetamine (METH). GABAergic neurons were immunohistochemically stained with parvalbumin antibody. Psychostimulant-induced hyperlocomotion was measured using an infrared sensor. Prenatal exposure (E15–E18) to the NMDA receptor antagonist MK-801 reduced the density of parvalbumin-immunoreactive neurons in rat medial prefrontal cortex on postnatal day 63 (P63) and enhanced PCP-induced hyperlocomotion but not the acute effects of METH on P63 or the development of behavioral sensitization. Prenatal exposure to MK-801 reduced the number of parvalbumin-immunoreactive neurons even on postnatal day 35 (P35) and did not enhance PCP-induced hyperlocomotion, the acute effects of METH on P35, or the development of behavioral sensitization to METH. These findings suggest that prenatal blockade of NMDA receptors disrupts GABAergic neurodevelopment in medial prefrontal cortex, and that this disruption of GABAergic development may be related to the enhancement of the locomotion-inducing effect of PCP in postpubertal but not juvenile offspring. GABAergic deficit is unrelated to the effects of METH. This GABAergic neurodevelopmental disruption and the enhanced PCP-induced hyperlocomotion in adult offspring prenatally exposed to MK-801 may prove useful as a new model of the neurodevelopmental process of pathogenesis of treatment-resistant schizophrenia via an NMDA-receptor-mediated hypoglutamatergic mechanism.
      datePublished:2007-03-06T00:00:00Z
      dateModified:2007-03-06T00:00:00Z
      pageStart:303
      pageEnd:316
      sameAs:https://doi.org/10.1007/s00213-007-0729-8
      keywords:
         Prenatal
         MK-801
         NMDA receptor
         Parvalbumin
         PCP
         METH
         Neurosciences
         Pharmacology/Toxicology
         Psychiatry
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00213-007-0729-8/MediaObjects/213_2007_729_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00213-007-0729-8/MediaObjects/213_2007_729_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00213-007-0729-8/MediaObjects/213_2007_729_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00213-007-0729-8/MediaObjects/213_2007_729_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00213-007-0729-8/MediaObjects/213_2007_729_Fig5_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00213-007-0729-8/MediaObjects/213_2007_729_Fig6_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00213-007-0729-8/MediaObjects/213_2007_729_Fig7_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00213-007-0729-8/MediaObjects/213_2007_729_Fig8_HTML.gif
      isPartOf:
         name:Psychopharmacology
         issn:
            1432-2072
            0033-3158
         volumeNumber:192
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Tomohiro Abekawa
            affiliation:
                  name:Hokkaido University
                  address:
                     name:Department of Psychiatry, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Koki Ito
            affiliation:
                  name:Hokkaido University
                  address:
                     name:Department of Psychiatry, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Shin Nakagawa
            affiliation:
                  name:Hokkaido University
                  address:
                     name:Department of Psychiatry, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Tsukasa Koyama
            affiliation:
                  name:Hokkaido University
                  address:
                     name:Department of Psychiatry, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Psychopharmacology
      issn:
         1432-2072
         0033-3158
      volumeNumber:192
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Hokkaido University
      address:
         name:Department of Psychiatry, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
         type:PostalAddress
      name:Hokkaido University
      address:
         name:Department of Psychiatry, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
         type:PostalAddress
      name:Hokkaido University
      address:
         name:Department of Psychiatry, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
         type:PostalAddress
      name:Hokkaido University
      address:
         name:Department of Psychiatry, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Tomohiro Abekawa
      affiliation:
            name:Hokkaido University
            address:
               name:Department of Psychiatry, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Koki Ito
      affiliation:
            name:Hokkaido University
            address:
               name:Department of Psychiatry, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
               type:PostalAddress
            type:Organization
      name:Shin Nakagawa
      affiliation:
            name:Hokkaido University
            address:
               name:Department of Psychiatry, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
               type:PostalAddress
            type:Organization
      name:Tsukasa Koyama
      affiliation:
            name:Hokkaido University
            address:
               name:Department of Psychiatry, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Psychiatry, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
      name:Department of Psychiatry, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
      name:Department of Psychiatry, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
      name:Department of Psychiatry, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(176)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

5s.